...it's a shame that Yahoo gives this low life a voice.
They will be required to run another trial, which they don't have the resources to do, and will have to hopefully find a partner to do it. The best news on Optina is no news.
You're an idiot. There is no news that is imminent, and it is highly unlike that they will release 20 Week MRI's from Open Label because they will be inconclusive and will only muddy the picture. All that matters are WOMAC scores, and those are not due until March & May.
..with strong data from STRUT & STRIDE this could be around $15.00 BEFORE any potential distribution/marketing deal or outright sale.
....2015 will tell the story for AMPE. In my opinion, the stock would be multiples higher currently, regardless of the STEP trial failure, if more seasoned, experienced and credible management were at the helm. The drug - Ampion - works, potentially dramatically so, for K-3 & 4 patients. That much I believe is obvious. The question is whether Macaluso and Vaughn can get it across the finish line.
I will give them credit for advancing Ampion as quickly as they have. More traditional management would likely have taken longer to get Ampion to where it is clinically. The flip side is in their haste they blew the STEP trial.
The science is solid. The Open Label 7 results are eye scratching - almost complete resolution of K-4 pain at 20 weeks.That is incredible, placebo control or no placebo control. But Wall Street will not bite until they see placebo controlled results. Ampion could have placebo controlled WOMAC scores of 60% give or take. That would be a game changer, and would make Synvisc obsolete overnight. Multiple injections will likely show much greater efficacy than single injection.
But the current reality is that you have a stock that is selling at multiple year lows, which is in part due to short selling, and in part due to lack of confidence in management. There is little institutional support, and likely won't be until we get closer to the STRUT results.
However, in my opinion, the current market cap, particularly when compared to other Biotechs, is absurd. IF the data from STRUT & STRIDE comes in significantly better than the SPRING trial, then you have a drug that should be a Blockbuster in the hands of Big Pharma. Maybe a Mega Blockbuster given all the other indications for use that could in short order be approved.
I think the science will rule out over management. In any worst case scenario, the drug in another Pharma's hands is worth much more than the current market cap. In the interim, we wait and suffer until we get data.
...we've heard for months now ad nauseum how Optina is inferior and will fail(who cares), but I've requested some of your astute research for Ben Gay, Advil, Heating Pads, Weight Loss, Icy Hot & WD-40 etc. for OAK, and have yet to hear you impart your wisdom upon us.
...a drug that should be a blockbuster, and a management team that has killed shareholders. With a more credible, seasoned, veteran Biotech CEO, this stock would be double or triple where it is now, regardless of STEP. We are paying a big price for the Macaluso factor.
The data, when it comes out, should be very strong. The scary thing is, where does the stock price go in the interim?
steed, I too have had numerous interactions with MM, but have also been in touch with institutional shareholders, clinical investigators(they are limited in what they can say) and the CITI analyst. I'm sure that MM has told you that WOMAC A pain reductions of 50% would be home run in the company's mind and Pharma's also, and that's what they are looking for. Many are looking for 60%+
A pain drug that achieves greater than 50% pain reduction with 20 weeks duration of action would be unprecedented and extremely valuable. These pain trials are simple to execute. It would be highly unlikely that 2 trials in a row would fail for logistical or administrative issues.
The science is solid, and the drug's efficacy is greatly enhanced through MI. The problem is waiting for STRUT & STRIDE results. Until then, the stock may be dead money selling at the pitiful that it currently is.
If you are long, and if you agree with super bashers Maurelius & Rogerxavier, then you are a true idiot, and should go short so your position matches your sentiment.
A retired ex-military novice investor? No, you're just an equal to ri66 in stupidity with your incessant posting.